• Onder Tonyali, Ugur Coskun, Nur Sener, Mevlude Inanc, Tulay Akman, Arife Ulas, Dogan Yazilitas, Oznur Bal, Mehmet Kucukoner, Nuriye Yildirim Ozdemir, Umut Demirci, Yusuf Gunaydin, Ramazan Yildiz, Halit Karaca, Olcun Umit Unal, Mahmut Gumus, Mustafa Benekli, and Suleyman Buyukberber.
• Division of Medical Oncology, Department of Internal Medicine, Gazi University Faculty of Medicine, Ankara, Turkey.
• Onkologie. 2013 Jan 1; 36 (10): 554-8.

BackgroundThe objective of this study was to identify prognostic factors affecting the recurrence-free survival (RFS) in patients who received a 52-week trastuzumab therapy for HER2-positive early stage breast cancer (EBC).Patients And MethodsThe medical records of all patients with EBC from 10 centers were analyzed. Pathologic and clinical tumor characteristics were evaluated in 424 female patients who received 52 weeks of adjuvant trastuzumab for HER2-positive EBC. Survival was estimated using the Kaplan-Meier method. Univariate analyses of RFS were performed with the log-rank test. Independent prognostic and predictive factors affecting RFS were assessed by Cox regression analysis.ResultsMedian follow-up time was 33.1 months (range 9.2-75.9 months). 3-year RFS and overall survival were 87 and 97%, respectively. In multivariate analysis, patients aged 70 years or over (p = 0.017, relative risk (RR) 2.7, 95% confidence interval (CI) 1.19-6.13), patients with > 9 positive lymph nodes (p = 0.001, RR 2.52, 95% CI 1.42-4.46), and those with progesterone receptor-negative tumors (p = 0.006, RR 2.33, 95% CI 1.27-4.27) had worse RFS.ConclusionIn spite of a 52-week adjuvant trastuzumab treatment, classic poor prognostic factors for invasive EBC remained as such in patients with HER2-positive EBC.© 2013 S. Karger GmbH, Freiburg.

35 keywords...

hide…